**THE CEO BRIEF: ANNA KEPNER**
**Headline:** Anna Kepner Is Dead. Her Patent Portfolio Just Made $400 Million.
**Impact:** U.S. medical device supply chain exposed as critically fragile.
**Why It Matters:** Anna Kepner, a 67-year-old retired biomedical engineer from Toledo, passed away last Tuesday. She held 14 patents—most notably for a specialized polymer used in arterial stents. The company holding her exclusive manufacturing license, *VascularCore*, had not secured a secondary source. Without Kepner’s proprietary process (unreplicable without her "black book"), production halts in 90 days. Competitors are already circling for a hostile acquisition. The CEO of VascularCore just announced a $400M emergency R&D fund—but sources say they already offered Kepner’s estate $50M for the trade secrets. She declined. The lesson: your IP is your leverage; your people are your only moat.
**Action:** Audit your key-person dependencies now.